Biotechnology
Compare Stocks
3 / 10Stock Comparison
IFRX vs ARGX vs OMAB
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Airlines, Airports & Air Services
IFRX vs ARGX vs OMAB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Airlines, Airports & Air Services |
| Market Cap | $192M | $48.72B | $5.16B |
| Revenue (TTM) | $28K | $5.60B | $15.96B |
| Net Income (TTM) | $-44M | $1.95B | $5.34B |
| Gross Margin | -261.1% | 88.3% | 75.6% |
| Operating Margin | -1735.9% | 15.0% | 56.0% |
| Forward P/E | — | 30.0x | 0.8x |
| Total Debt | $898K | $83M | $13.59B |
| Cash & Equiv. | $16M | $3.49B | $3.10B |
IFRX vs ARGX vs OMAB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| InflaRx N.V. (IFRX) | 100 | 30.0 | -70.0% |
| argenx SE (ARGX) | 100 | 359.0 | +259.0% |
| Grupo Aeroportuario… (OMAB) | 100 | 303.5 | +203.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IFRX vs ARGX vs OMAB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IFRX is the clearest fit if your priority is momentum.
- +77.9% vs OMAB's +16.1%
ARGX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.52
- Rev growth 90.1%, EPS growth 53.6%, 3Y rev CAGR 116.4%
- 33.2% 10Y total return vs OMAB's 192.8%
OMAB is the clearest fit if your priority is value and dividends.
- Lower P/E (0.8x vs 30.0x)
- 5.0% yield; 2-year raise streak; the other 2 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 90.1% revenue growth vs IFRX's -83.0% | |
| Value | Lower P/E (0.8x vs 30.0x) | |
| Quality / Margins | 34.9% margin vs IFRX's -1.6K% | |
| Stability / Safety | Beta 0.52 vs IFRX's 2.08, lower leverage | |
| Dividends | 5.0% yield; 2-year raise streak; the other 2 pay no meaningful dividend | |
| Momentum (1Y) | +77.9% vs OMAB's +16.1% | |
| Efficiency (ROA) | 29.1% ROA vs IFRX's -62.4%, ROIC 18.3% vs -104.4% |
IFRX vs ARGX vs OMAB — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ARGX leads in 2 of 6 categories
OMAB leads 1 • IFRX leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ARGX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
OMAB is the larger business by revenue, generating $16.0B annually — 566656.5x IFRX's $28,173. ARGX is the more profitable business, keeping 34.9% of every revenue dollar as net income compared to IFRX's -1555.8%. On growth, ARGX holds the edge at +78.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $28,173 | $5.6B | $16.0B |
| EBITDAEarnings before interest/tax | -$49M | $999M | $9.8B |
| Net IncomeAfter-tax profit | -$44M | $2.0B | $5.3B |
| Free Cash FlowCash after capex | -$35M | $755M | $5.5B |
| Gross MarginGross profit ÷ Revenue | -261.1% | +88.3% | +75.6% |
| Operating MarginEBIT ÷ Revenue | -1735.9% | +15.0% | +56.0% |
| Net MarginNet income ÷ Revenue | -1555.8% | +34.9% | +33.5% |
| FCF MarginFCF ÷ Revenue | -1257.6% | +13.5% | +34.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -82.0% | +78.7% | -0.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -61.3% | +8.4% | +2.6% |
Valuation Metrics
OMAB leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 16.7x trailing earnings, OMAB trades at a 58% valuation discount to ARGX's 40.1x P/E. On an enterprise value basis, OMAB's 10.1x EV/EBITDA is more attractive than ARGX's 46.6x.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $192M | $48.7B | $5.2B |
| Enterprise ValueMkt cap + debt − cash | $174M | $45.3B | $5.8B |
| Trailing P/EPrice ÷ TTM EPS | -3.42x | 40.11x | 16.67x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 29.95x | 0.77x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.44x |
| EV / EBITDAEnterprise value multiple | — | 46.60x | 10.14x |
| Price / SalesMarket cap ÷ Revenue | 5786.44x | 11.70x | 5.58x |
| Price / BookPrice ÷ Book value/share | 3.65x | 7.10x | 7.79x |
| Price / FCFMarket cap ÷ FCF | — | 57.71x | 12.09x |
Profitability & Efficiency
Evenly matched — ARGX and OMAB each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
OMAB delivers a 50.6% return on equity — every $100 of shareholder capital generates $51 in annual profit, vs $-82 for IFRX. ARGX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to OMAB's 1.19x. On the Piotroski fundamental quality scale (0–9), OMAB scores 6/9 vs IFRX's 1/9, reflecting solid financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -81.8% | +33.7% | +50.6% |
| ROA (TTM)Return on assets | -62.4% | +29.1% | +17.6% |
| ROICReturn on invested capital | -104.4% | +18.3% | +31.7% |
| ROCEReturn on capital employed | -94.0% | +15.1% | +35.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.02x | 0.01x | 1.19x |
| Net DebtTotal debt minus cash | -$15M | -$3.4B | $10.5B |
| Cash & Equiv.Liquid assets | $16M | $3.5B | $3.1B |
| Total DebtShort + long-term debt | $897,532 | $83M | $13.6B |
| Interest CoverageEBIT ÷ Interest expense | -1297.60x | 326.52x | 6.08x |
Total Returns (Dividends Reinvested)
ARGX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ARGX five years ago would be worth $29,856 today (with dividends reinvested), compared to $7,320 for IFRX. Over the past 12 months, IFRX leads with a +77.9% total return vs OMAB's +16.1%. The 3-year compound annual growth rate (CAGR) favors ARGX at 24.7% vs IFRX's -13.5% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | +143.1% | -6.3% | -1.8% |
| 1-Year ReturnPast 12 months | +77.9% | +26.4% | +16.1% |
| 3-Year ReturnCumulative with dividends | -35.4% | +93.9% | +40.1% |
| 5-Year ReturnCumulative with dividends | -26.8% | +198.6% | +157.8% |
| 10-Year ReturnCumulative with dividends | -82.3% | +3323.1% | +192.8% |
| CAGR (3Y)Annualised 3-year return | -13.5% | +24.7% | +11.9% |
Risk & Volatility
Evenly matched — IFRX and ARGX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ARGX is the less volatile stock with a 0.52 beta — it tends to amplify market swings less than IFRX's 2.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IFRX currently trades 90.1% from its 52-week high vs OMAB's 79.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.08x | 0.52x | 0.62x |
| 52-Week HighHighest price in past year | $2.94 | $934.62 | $134.99 |
| 52-Week LowLowest price in past year | $0.71 | $510.06 | $89.53 |
| % of 52W HighCurrent price vs 52-week peak | +90.1% | +84.2% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 79.7 | 57.3 | 40.5 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 330K | 92K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: IFRX as "Buy", ARGX as "Buy", OMAB as "Buy". Consensus price targets imply 33.7% upside for ARGX (target: $1052) vs -24.5% for IFRX (target: $2). OMAB is the only dividend payer here at 5.02% yield — a key consideration for income-focused portfolios.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $2.00 | $1052.30 | $127.00 |
| # AnalystsCovering analysts | 15 | 36 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | +5.0% |
| Dividend StreakConsecutive years of raises | — | — | 2 |
| Dividend / ShareAnnual DPS | — | — | $92.57 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.0% |
ARGX leads in 2 of 6 categories (Income & Cash Flow, Total Returns). OMAB leads in 1 (Valuation Metrics). 2 tied.
IFRX vs ARGX vs OMAB: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IFRX or ARGX or OMAB a better buy right now?
For growth investors, argenx SE (ARGX) is the stronger pick with 90.
1% revenue growth year-over-year, versus -83. 0% for InflaRx N. V. (IFRX). Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. (OMAB) offers the better valuation at 16. 7x trailing P/E (0. 8x forward), making it the more compelling value choice. Analysts rate InflaRx N. V. (IFRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IFRX or ARGX or OMAB?
On trailing P/E, Grupo Aeroportuario del Centro Norte, S.
A. B. de C. V. (OMAB) is the cheapest at 16. 7x versus argenx SE at 40. 1x. On forward P/E, Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. is actually cheaper at 0. 8x.
03Which is the better long-term investment — IFRX or ARGX or OMAB?
Over the past 5 years, argenx SE (ARGX) delivered a total return of +198.
6%, compared to -26. 8% for InflaRx N. V. (IFRX). Over 10 years, the gap is even starker: ARGX returned +33. 2% versus IFRX's -82. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IFRX or ARGX or OMAB?
By beta (market sensitivity over 5 years), argenx SE (ARGX) is the lower-risk stock at 0.
52β versus InflaRx N. V. 's 2. 08β — meaning IFRX is approximately 296% more volatile than ARGX relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 119% for Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. — giving it more financial flexibility in a downturn.
05Which is growing faster — IFRX or ARGX or OMAB?
By revenue growth (latest reported year), argenx SE (ARGX) is pulling ahead at 90.
1% versus -83. 0% for InflaRx N. V. (IFRX). On earnings-per-share growth, the picture is similar: argenx SE grew EPS 53. 6% year-over-year, compared to 8. 4% for Grupo Aeroportuario del Centro Norte, S. A. B. de C. V.. Over a 3-year CAGR, ARGX leads at 116. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IFRX or ARGX or OMAB?
Grupo Aeroportuario del Centro Norte, S.
A. B. de C. V. (OMAB) is the more profitable company, earning 33. 5% net margin versus -1555. 8% for InflaRx N. V. — meaning it keeps 33. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OMAB leads at 56. 0% versus -1735. 9% for IFRX. At the gross margin level — before operating expenses — ARGX leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IFRX or ARGX or OMAB more undervalued right now?
On forward earnings alone, Grupo Aeroportuario del Centro Norte, S.
A. B. de C. V. (OMAB) trades at 0. 8x forward P/E versus 30. 0x for argenx SE — 29. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARGX: 33. 7% to $1052. 30.
08Which pays a better dividend — IFRX or ARGX or OMAB?
In this comparison, OMAB (5.
0% yield) pays a dividend. IFRX, ARGX do not pay a meaningful dividend and should not be held primarily for income.
09Is IFRX or ARGX or OMAB better for a retirement portfolio?
For long-horizon retirement investors, Grupo Aeroportuario del Centro Norte, S.
A. B. de C. V. (OMAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 62), 5. 0% yield, +192. 8% 10Y return). InflaRx N. V. (IFRX) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OMAB: +192. 8%, IFRX: -82. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IFRX and ARGX and OMAB?
These companies operate in different sectors (IFRX (Healthcare) and ARGX (Healthcare) and OMAB (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: IFRX is a small-cap quality compounder stock; ARGX is a mid-cap high-growth stock; OMAB is a small-cap deep-value stock. OMAB pays a dividend while IFRX, ARGX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.